{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T14:11:47Z","timestamp":1742393507427},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T00:00:00Z","timestamp":1418688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s12032-014-0353-5","type":"journal-article","created":{"date-parts":[[2014,12,15]],"date-time":"2014-12-15T11:19:39Z","timestamp":1418642379000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas"],"prefix":"10.1007","volume":"32","author":[{"given":"Hou","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui lai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"353_CR1","first-page":"198","volume":"336","author":"B Coiffier","year":"1999","unstructured":"Coiffier B, Thieblemont C, Felman P, Salles G, Berger F. Indolent non-follicular lymphomas: characteristics, treatment and outcome. Semin Hematol. 1999;336:198\u2013208.","journal-title":"Semin Hematol"},{"key":"353_CR2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"PW Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140\u20137.","journal-title":"J Clin Oncol"},{"issue":"10","key":"353_CR3","first-page":"5287","volume":"34","author":"N Kunami","year":"2014","unstructured":"Kunami N, Katsuya H, Nogami R, et al. Promise of combining a Bcl-2 family inhibitor with\u00a0bortezomib\u00a0or SAHA for adult T-cell leukemia\/lymphoma. Anticancer Res. 2014;34(10):5287\u201394.","journal-title":"Anticancer Res"},{"key":"353_CR4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","volume":"115","author":"N Bella Di","year":"2010","unstructured":"Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475\u201380.","journal-title":"Blood"},{"key":"353_CR5","doi-asserted-by":"crossref","unstructured":"Holkova B, Kmieciak M, Perkins EB, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and \u201cnonhybrid\u201d (Bolus) infusion schedule of alvocidib (Flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014;20(22):5652\u201362.","DOI":"10.1158\/1078-0432.CCR-14-0805"},{"key":"353_CR6","doi-asserted-by":"crossref","unstructured":"Ribrag V, Tilly H, Casasnovas O, et al. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l\u2019Adulte (GELA). Eur J Cancer. 2013;49(4):904\u201310.","DOI":"10.1016\/j.ejca.2012.11.015"},{"key":"353_CR7","doi-asserted-by":"crossref","unstructured":"Knapp CM, Whitehead KA, et al. In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin\u00a0B-cell\u00a0lymphoma. Expert Opin Drug Deliv. 2014;95(4):1\u201315.","DOI":"10.1517\/17425247.2014.945419"},{"issue":"4","key":"353_CR8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12185-014-1646-3","volume":"100","author":"K Ichikawa","year":"2014","unstructured":"Ichikawa K, Noguchi M, Koike M, et al. Rituximab\u00a0plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large\u00a0B-cell\u00a0lymphoma\u00a0lead to prolonged progression-free survival. Int J Hematol. 2014;100(4):370\u20138.","journal-title":"Int J Hematol"},{"key":"353_CR9","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","volume":"14","author":"MS Czuczman","year":"2008","unstructured":"Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561\u201370.","journal-title":"Clin Cancer Res"},{"key":"353_CR10","doi-asserted-by":"crossref","unstructured":"Furtado M, Johnson R, Kruger A. Addition of\u00a0bortezomib\u00a0to standard dose chop chemotherapy improves response and survival in relapsed mantle cell\u00a0lymphoma. Br J Haematol 2014 Aug 22.","DOI":"10.1111\/bjh.13101"},{"key":"353_CR11","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807\u201312.","journal-title":"Blood"},{"key":"353_CR12","doi-asserted-by":"crossref","unstructured":"Bertrand Coiffi er, Evgenii A Osmanov, Xiaonan Hong, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011;12: 773\u201384.","DOI":"10.1016\/S1470-2045(11)70150-4"},{"issue":"16","key":"353_CR13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1517\/14656566.2014.965142","volume":"15","author":"P Bose","year":"2014","unstructured":"Bose P, Batalo MS, Holkova B, et al. Bortezomib\u00a0for the treatment of non- Hodgkin\u2019s\u00a0lymphoma. Expert Opin Pharmacother. 2014;15(16):2443\u201359.","journal-title":"Expert Opin Pharmacother"},{"key":"353_CR14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"353_CR15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","volume":"168","author":"D Pulte","year":"2008","unstructured":"Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008;168:469\u201376.","journal-title":"Arch Intern Med"},{"key":"353_CR16","doi-asserted-by":"crossref","unstructured":"Goda AE, Erikson RL, Sakai T, et al. Preclinical evaluation of\u00a0bortezomib\/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Mol Oncol 2014 Sep 6. pii: S1574-7891(14)00205-1.","DOI":"10.1016\/j.molonc.2014.08.010"},{"issue":"6","key":"353_CR17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.12991","volume":"166","author":"M Craig","year":"2014","unstructured":"Craig M, Hanna WT, Cabanillas F, et al. Phase II study of\u00a0bortezomib\u00a0in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular\u00a0lymphoma. Br J Haematol. 2014;166(6):920\u20138.","journal-title":"Br J Haematol"},{"key":"353_CR18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","volume":"115","author":"DB Nicholas","year":"2010","unstructured":"Nicholas DB, Raymond T, Kathryn K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475\u201380.","journal-title":"Blood"},{"issue":"25","key":"353_CR19","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29(25):3389\u201395.","journal-title":"J Clin Oncol"},{"key":"353_CR20","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"WF Jonathan","year":"2011","unstructured":"Jonathan WF, Julie MV, Jennifer LK, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807\u201312.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0353-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0353-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T09:03:34Z","timestamp":1566119014000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0353-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["353"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0353-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,16]]},"article-number":"353"}}